New study observes patients getting nasal stem cell therapy for brain conditions

NCT ID NCT07521384

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and changes in a key inflammation marker (TNF-α) over time. The goal is to gather real-world data on how these regenerative treatments affect the body, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MuSE cell derived exosomes, MuSE stem cells, or combination therapy delivered intranasally via the ViaNase device

What this could lead to

If successful, this study could provide early evidence on whether these regenerative therapies are safe and reduce inflammation in the brain, pointing toward future treatments for conditions like traumatic brain injury, multiple sclerosis, and Alzheimer's.

What could go wrong

This is a small, early observational study (36 participants) that does not assign treatment or compare against a placebo. Results may not prove effectiveness or apply to broader populations. Risks include unknown side effects from the intranasal delivery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXIC ISCHEMIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease autism brain hypoxia - ischemia Brain Injuries, Traumatic cerebral palsy multiple sclerosis myeloid sarcoma nervous system disorder Parkinson disease perinatal asphyxia stroke disorder traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stem Solutions

    Monterrey, Nuevo León, Mexico